Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic ReviewsShunlong Ou, Qian Jiang, Hua Wei et al.|Frontiers in Immunology|2022Cited by 22